Gilead Sciences GILD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.74B+3.5% | $29.44B+2.4% | $29.09B+2.8% | $28.86B+3.8% | $28.74B+4.7% | ||
| $6.14B-1.6% | $6.23B-0.3% | $6.19B-8.4% | $6.2B-8.2% | $6.24B-6.2% | ||
| $23.6B+4.9% | $23.21B+3.1% | $22.9B+6.3% | $22.67B+7.7% | $22.5B+8.1% | ||
| 79.4%+1.1pp | 78.8%+0.6pp | 78.7%+2.6pp | 78.5%+2.8pp | 78.3%+2.5pp | ||
| $5.97B-0.1% | $5.77B-5.2% | $5.89B+1.6% | $5.96B+5.1% | $5.98B-2.8% | ||
| $19.37B-5.6% | $19.42B-28.3% | $18.6B-32.3% | $20.81B-17.6% | $20.51B-20.7% | ||
| $10.37B+26.2% | $10.02B+503% | $10.49B+1,176% | $8.05B+215% | $8.22B+421% | ||
| 34.9%+6.3pp | 34%+28.3pp | 36.1%+33.2pp | 27.9%+18.7pp | 28.6%+22.9pp | ||
| $1.01B+2.1% | $1.03B+4.8% | $1.02B+3.9% | $1B+2.7% | $984M+1.7% | ||
| $1.36B— | $798M— | —— | —— | —— | ||
| $10.73B+57.2% | $9.8B+1,320% | $9.89B+5,517% | $7.2B+368% | $6.83B+536% | ||
| $1.62B+87.9% | $1.39B+559% | $1.78B+2,719% | $890M+75.9% | $860M+39.4% | ||
| $9.22B+54.5% | $8.51B+1,673% | $8.11B+6,337% | $6.31B+499% | $5.97B+1,132% | ||
| 31%+10.2pp | 28.9%+27.2pp | 27.9%+27.4pp | 21.9%+18.1pp | 20.8%+19.0pp | ||
| $7.34+54.5% | $6.77+1,730% | $6.45+7,962% | $5.02+520% | $4.75+1,257% | ||
| $7.42+55.6% | $6.85+1,751% | $6.51+6,410% | $5.05+494% | $4.77+1,093% | ||
| 5B0.0% | 5B+0.3% | 5B+0.3% | 5B+0.2% | 5B0.0% | ||
| 5B-0.3% | 5B-0.2% | 5B-0.2% | 5B-0.1% | 5B-0.1% | ||
| $877M+10.2% | $1.02B-78.1% | $484M-90.4% | $819M-82.2% | $796M-83.4% | ||
| $2.39B-0.1% | $2.39B+0.2% | $2.39B+0.3% | $2.39B+0.2% | $2.39B0.0% | ||
| —— | —— | -$97M+94.7% | -$1.33B-0.4% | -$1.32B+4.5% | ||
| $366M-4.7% | $370M-2.9% | $375M-0.5% | $379M+2.7% | $384M+8.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $474M+265% | -$21M-104% | -$284M— | ||
| —— | —— | $706M+488% | $47M+161% | $39M-95.3% | ||
| -$1.59B— | -$2.11B— | —— | —— | —— | ||
| $865M+43.2% | $1.04B+143% | $1.14B+125% | $709M+40.7% | $604M-8.5% | ||
| $318M+51.4% | $311M+20.1% | $421M— | $110M— | $210M— | ||
| -$8.56B— | -$7.75B— | —— | —— | —— | ||
| -$2.61B-57.4% | -$4.79B-39.0% | -$3.18B+19.4% | -$3.47B+0.1% | -$1.66B+54.6% | ||
| $10.81B+4.2% | $10.02B-7.5% | $9.67B-3.5% | $9.87B+32.1% | $10.37B+22.2% | ||
| -$572M-76.0% | -$480M-36.0% | -$272M+68.4% | -$269M+67.6% | -$325M+63.2% | ||
| —— | —— | —— | —— | -$30M-233% | ||
| $1.61B+8.9% | $1.92B+67.1% | $2.04B+115% | $1.91B+101% | $1.48B+48.0% | ||
| $4.03B+2.4% | $4B+2.2% | $3.98B+2.4% | $3.96B+2.6% | $3.94B+2.8% | ||
| $4.18B— | $3.65B— | —— | —— | —— | ||
| $906M-15.3% | $1.07B-77.9% | $536M-89.4% | $939M-79.4% | $1.07B-77.0% | ||
| $576M+10.3% | $563M+7.6% | $505M-14.6% | $499M-12.8% | $522M-10.2% | ||
| $322M-39.0% | $408M-3.3% | $549M+99.6% | $550M+112% | $528M+87.9% | ||
| $91M— | $55M— | —— | —— | —— | ||
| -$443M-29.9% | -$440M-56.6% | -$424M-58.2% | -$369M-39.8% | -$341M-31.2% | ||
| $3.37B— | $854M— | —— | —— | —— | ||
| $2.79B-25.2% | $1.79B-9.2% | $1.79B-9.0% | $1.89B-53.9% | $3.73B+65.9% | ||
| $5.79B+0.5% | $5.8B-1.8% | $5.86B+3.2% | $5.91B+3.0% | $5.77B-0.4% | ||
| $29.74B+3.5% | $29.44B+2.4% | $29.09B+2.8% | $28.86B+3.8% | $28.74B+4.7% | ||
| $903M+5.4% | $894M+7.1% | $886M+8.8% | $872M+9.0% | $857M+8.8% | ||
| $10.37B+26.2% | $10.02B+503% | $10.49B+1,176% | $8.05B+215% | $8.22B+421% | ||
| $10.74B+24.8% | $10.39B+409% | $10.87B+806% | $8.43B+139% | $8.61B+175% | ||
| $10.74B+24.8% | $10.39B+409% | $10.87B+806% | $8.43B+139% | $8.61B+175% | ||
| 36.1%+6.2pp | 35.3%+28.2pp | 37.4%+33.1pp | 29.2%+16.5pp | 29.9%+18.6pp | ||
| $10.37B+26.2% | $10.02B+503% | $10.49B+1,176% | $8.05B+215% | $8.22B+421% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
